Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Masters of Immunology

  • Masters of Immunology
    NF-κB, an Active Player in Human Cancers
    Yifeng Xia, Shen Shen and Inder M. Verma
    Cancer Immunol Res September 1 2014 2 (9) 823-830; DOI:10.1158/2326-6066.CIR-14-0112

Cancer Immunology at the Crossroads: Complementary Therapeutic Modalities

  • Cancer Immunology at the Crossroads: Complementary Therapeutic Modalities
    Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
    Chad Tang, Xiaohong Wang, Hendrick Soh, Steven Seyedin, Maria Angelica Cortez, Sunil Krishnan, Erminia Massarelli, David Hong, Aung Naing, Adi Diab, Daniel Gomez, Huiping Ye, John Heymach, Ristuko Komaki, James P. Allison, Padmanee Sharma and James W. Welsh
    Cancer Immunol Res September 1 2014 2 (9) 831-838; DOI:10.1158/2326-6066.CIR-14-0069

Priority Brief

  • Priority Brief
    Antigen-Specific Culture of Memory-like CD8 T Cells for Adoptive Immunotherapy
    Adam J. Litterman, David M. Zellmer, Rebecca S. LaRue, Stephen C. Jameson and David A. Largaespada
    Cancer Immunol Res September 1 2014 2 (9) 839-845; DOI:10.1158/2326-6066.CIR-14-0038

    Litterman and colleagues created a cocktail of cytokines and small molecules for ex vivo expansion of naïve or antigen-specific T cells into polyclonal cytotoxic T cells with memory phenotype, and greater proliferative and antitumor activity in vivo.

Research Articles

  • Research Articles | AuthorChoice
    In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
    Changyu Wang, Kent B. Thudium, Minhua Han, Xi-Tao Wang, Haichun Huang, Diane Feingersh, Candy Garcia, Yi Wu, Michelle Kuhne, Mohan Srinivasan, Sujata Singh, Susan Wong, Neysa Garner, Heidi Leblanc, R. Todd Bunch, Diann Blanset, Mark J. Selby and Alan J. Korman
    Cancer Immunol Res September 1 2014 2 (9) 846-856; DOI:10.1158/2326-6066.CIR-14-0040

    Wang and colleagues describe the development and comprehensive preclinical characterization of nivolumab, a fully human IgG4 (S228P) anti-PD-1 receptor blocking mAb, the antitumor activity and safety profile of which has been demonstrated in human clinical trials in various solid tumors.

  • Research Articles | AuthorChoice
    Mechanisms That Can Promote Peripheral B-cell Lymphoma in ATM-Deficient Mice
    Suprawee Tepsuporn, Jiazhi Hu, Monica Gostissa and Frederick W. Alt
    Cancer Immunol Res September 1 2014 2 (9) 857-866; DOI:10.1158/2326-6066.CIR-14-0090

    Tepsuporn, Hu, and colleagues generated the first mouse models for B-cell lymphoma in the context of ATM deficiency, and they provide a detailed characterization of the mature B-cell lymphomas that arise, revealing an unanticipated mechanism for the developmental propagation of V(D)J recombination-initiated DNA double-strand breaks.

  • Research Articles
    Targeting 4-1BB Costimulation to the Tumor Stroma with Bispecific Aptamer Conjugates Enhances the Therapeutic Index of Tumor Immunotherapy
    Brett Schrand, Alexey Berezhnoy, Randall Brenneman, Anthony Williams, Agata Levay, Ling-Yuan Kong, Ganesh Rao, Shouhao Zhou, Amy B. Heimberger and Eli Gilboa
    Cancer Immunol Res September 1 2014 2 (9) 867-877; DOI:10.1158/2326-6066.CIR-14-0007

    Schrand and colleagues report the efficacy in five murine tumor models of an immunotherapeutic approach whereby systemic administration of tumor stroma-targeted 4-1BB aptamer conjugates, which target disseminated tumor lesions, elicits potent antitumor immunity with minimal dose-limiting toxicity.

  • Research Articles
    CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells
    Juan Du, Sandra Lopez-Verges, Brandelyn N. Pitcher, Jeffrey Johnson, Sin-Ho Jung, Lili Zhou, Katharine Hsu, Myron S. Czuczman, Bruce Cheson, Lawrence Kaplan, Lewis L. Lanier and Jeffrey M. Venstrom
    Cancer Immunol Res September 1 2014 2 (9) 878-889; DOI:10.1158/2326-6066.CIR-13-0158

    Du and colleagues report that a “missing ligand” genotype predictive of unlicensed NK cells was associated with higher progression-free survival in 101 follicular lymphoma patients treated with rituximab-containing mAb combinations, and that rituximab triggered responses in vitro from healthy-donor unlicensed NK cells.

  • Research Articles
    IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization
    Hanako Ohmatsu, Daniel Humme, Nicholas Gulati, Juana Gonzalez, Markus Möbs, Mayte Suárez-Fariñas, Irma Cardinale, Hiroshi Mitsui, Emma Guttman-Yassky, Wolfram Sterry and James G. Krueger
    Cancer Immunol Res September 1 2014 2 (9) 890-900; DOI:10.1158/2326-6066.CIR-13-0199-T

    Ohmatsu and colleagues report the consistently high and increasing expression of IL32 in cutaneous T-cell lymphoma mycosis fungoides (MF) compared with benign inflammatory skin diseases, and these findings correlate with increases in IFNγ mRNA, suggesting that IL32 may be an autocrine cytokine in MF progression.

  • Research Articles
    STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer
    Dinesh Chandra, Wilber Quispe-Tintaya, Arthee Jahangir, Denise Asafu-Adjei, Ilyssa Ramos, Herman O. Sintim, Jie Zhou, Yoshihiro Hayakawa, David K.R. Karaolis and Claudia Gravekamp
    Cancer Immunol Res September 1 2014 2 (9) 901-910; DOI:10.1158/2326-6066.CIR-13-0123

    Chandra, Quispe-Tintaya, and colleagues show that stimulator of IFN genes (STING) ligand c-di-GMP activated caspase-3, stimulated T cells, and nearly completely eliminated all metastases in mouse breast cancer model 4T1, when combined with Listeria monocytogenes–based Mage-b vaccine in a therapeutic setting.

  • Research Articles | AuthorChoice
    Episomal Expression of Truncated Listeriolysin O in LmddA-LLO–E7 Vaccine Enhances Antitumor Efficacy by Preferentially Inducing Expansions of CD4+FoxP3− and CD8+ T Cells
    Zhisong Chen, Laurent Ozbun, Namju Chong, Anu Wallecha, Jay A. Berzofsky and Samir N. Khleif
    Cancer Immunol Res September 1 2014 2 (9) 911-922; DOI:10.1158/2326-6066.CIR-13-0197

    Chen and colleagues developed an improved, attenuated L. monocytogenes–based vaccine that induced the regression of established mouse TC-1 tumors; they show that listeriolysin O serves as a vaccine adjuvant that decreases Treg frequency by inducing the expansion of non-Treg T cells.

Correction

  • Correction
    Correction: Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
    Cancer Immunol Res September 1 2014 2 (9) 923-923; DOI:10.1158/2326-6066.CIR-14-0141

Back to top
PreviousNext
Cancer Immunology Research: 2 (9)
September 2014
Volume 2, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Jump to

  • Masters of Immunology
  • Cancer Immunology at the Crossroads: Complementary Therapeutic Modalities
  • Priority Brief
  • Research Articles
  • Correction
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Characterization of Murine Syngeneic Tumor Models
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement